A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats.
The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening.
Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM.
The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM.
For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver.
Researchers will also look for:
* the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment
* the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment.
This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends.
Each participant will be in the study as long as they benefit from the treatment.
Participants will visit the study site:
* once before the treatment starts
* 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends.
* then 2 more times with a gap of 1 month between the visits after the treatment ends.
During the study, the study doctors and their team will:
* check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO)
* ask the participants questions about how they are feeling and what adverse events are they having
An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.

Start Date30 Jun 2025

Sponsor / Collaborator

Bayer AG

NCT06412666

/ RecruitingPhase 2/3

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Start Date29 May 2024

Sponsor / Collaborator

Cytokinetics, Inc.

NCT06116968

/ CompletedPhase 3

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

Start Date14 Nov 2023

Sponsor / Collaborator

Corxel Pharmaceuticals (Shanghai) Co., Ltd

100 Clinical Results associated with Aficamten

100 Translational Medicine associated with Aficamten

100 Patents (Medical) associated with Aficamten

109

Literatures (Medical) associated with Aficamten

01 Apr 2026·AMERICAN JOURNAL OF CARDIOLOGY

Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials

Article

Author: Salciccioli, Louis ; Fahim, Md ; Khouri, Peter ; Gorantla, Asher ; Eldawud, Daoud ; Wang, Roy ; Wahadneh, Omar ; Sharma, Nischal

Myosin inhibitors represent a novel therapeutic class for hypertrophic cardiomyopathy (HCM). While both mavacamten and aficamten have been evaluated in randomized trials, comparative evidence across the 2 agents remains limited. We performed a systematic review and meta-analysis of 8 randomized controlled trials of myosin inhibitors in HCM. Outcomes included improvement in the New York Heart Association (NYHA) functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), postexercise and resting left ventricular outflow tract (LVOT) gradients, mean rest LVOT peak gradient, mean Valsalva LVOT peak gradient, change in left ventricular ejection fraction (LVEF), peak oxygen uptake, N-terminal pro-B-type natriuretic peptide (NT-proBNP), treatment-emergent adverse events, and serious adverse events. Pooled effects were estimated twice using random-effects models, once stratified by drug and once pooled altogether. Results showed that myosin inhibitors improved clinical and hemodynamic outcomes versus placebo. Both mavacamten and aficamten yielded improvements in New York Heart Association functional class and KCCQ-CSS, while reducing LVOT gradients and proBNP levels. Effect magnitudes were generally larger with mavacamten; aficamten demonstrated concordant but smaller effects and was the only agent to increase peak oxygen uptake. Safety was favorable for both agents, with pooled estimates indicating a marginally more favorable safety profile for aficamten. In conclusion, myosin inhibitors improve functional status, quality of life, and hemodynamics in HCM with an acceptable safety profile. Mavacamten generally demonstrates more robust benefits, while aficamten appears to have a more favorable safety profile. Additional trials directly comparing these agents are warranted to better clarify relative efficacy and safety.

01 Mar 2026·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aficamten and the Future of Obstructive Hypertrophic Cardiomyopathy Management

Author: Saberi, Sara

01 Mar 2026·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aficamten in Obstructive Hypertrophic Cardiomyopathy

Article

Author: Claggett, Brian L ; Costabel, Juan Pablo ; Kulac, Ian J ; de Barros Correia, Edileide ; Bilen, Ozlem ; Schulze, P Christian ; Wohltman, Amy ; Solomon, Scott D ; Peña-Peña, Maria Luisa ; Reant, Patricia ; Lakdawala, Neal K ; Garcia-Pavia, Pablo ; Heitner, Stephen B ; Lewis, Gregory D ; Kupfer, Stuart ; Mann, Amy ; Malik, Fady I ; Poulsen, Steen H ; Masri, Ahmad ; Hegde, Sheila M ; Burroughs, Melissa ; Sohn, Regina ; Barriales-Villa, Roberto ; Fifer, Michael A ; Berhane, Indrias ; Maron, Martin S ; Nassif, Michael E ; Merkely, Bela ; Elliott, Perry ; Nair, Ajith ; Wang, Andrew ; Jacoby, Daniel L ; Dybro, Anne

BACKGROUND:

For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation. The MAPLE-HCM trial showed greater improvement in exercise capacity and secondary endpoints for aficamten monotherapy vs metoprolol monotherapy.

OBJECTIVES:

The purpose of this study was to evaluate the effects of aficamten vs metoprolol across multiple clinically relevant and patient-centric measures of disease burden in oHCM.

METHODS:

Patients with oHCM and left ventricular outflow tract gradient (LVOT-G) ≥30 mm Hg at rest and/or ≥50 mm Hg with Valsalva were randomly assigned to aficamten (n = 88) or metoprolol (n = 87). Dose titration was based on vital signs and echocardiograms. Assessment of clinical response by treatment arm was based on improvement in multiple parameters reflecting oHCM disease burden: LVOT-G <30 mm Hg at rest and <50 mm Hg with Valsalva; ≥1 class improvement in NYHA functional class and/or ≥10-point improvement in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS); ≥50% reduction in N-terminal pro-B-type natriuretic peptide; ≥1.0 mL/kg/min increase in peak oxygen consumption (pVO₂); and ≥10% reduction in left atrial volume index. Clinical response was classified by number of efficacy outcomes achieved: nonresponder (none), limited (1 or 2), positive (3 or 4), or complete (all 5).

RESULTS:

Baseline characteristics were similar for both treatment groups. For the overall cohort, mean age was 58 ± 13.2 years; 73 (42%) were women, 103 (70%) were in NYHA functional class II and 52 (30%) in class III, mean pVO₂ was 19.9 ± 5.1 mL/kg/min, and mean KCCQ-CSS score was 66 ± 16. At 24 weeks, aficamten treatment was associated with greater benefits in all efficacy outcome measures, with numbers needed to treat ranging from 1.5 to 5.0 relative to metoprolol treatment. Patients treated with aficamten were more likely to be either positive or complete responders compared with patients treated with metoprolol (78% vs 3%, respectively; P < 0.001).

CONCLUSIONS:

In patients with symptomatic oHCM, aficamten monotherapy led to superior and rapid treatment benefits across several clinically relevant outcome measures of disease burden compared with metoprolol. These observations support the emerging role of aficamten as monotherapy for oHCM. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; NCT05767346).

288

News (Medical) associated with Aficamten

31 Mar 2026

·allsci.com

Hengrui, Braveheart’s cardiac myosin inhibitor shows stronng early efficacy against cardiomyopathy

Hengrui Pharma and Braveheart Bio reported Phase II results for HRS-1893 (BHB-1893), a selective small-molecule cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy, the companies said on March 30. The data, from a 42-patient open-label dose-ranging study (NCT06516068), were presented as a late-breaking clinical research session at the American College of Cardiology Annual Scientific Session. Across three dose groups over 12 weeks, HRS-1893 produced complete Valsalva left ventricular outflow tract gradient (LVOT-G) responses — defined as a reduction below 30 mmHg — in 50% to 86% of patients, according to the companies. Mean LVEF declined between 1.8% and 2.7% across groups, and no patient recorded an ejection fraction below 55% during the core study period. The companies reported that average Valsalva LVOT-G fell below 30 mmHg as early as day 5. In Group 2, the 40 mg twice-daily cohort selected for an open-label extension, peak oxygen uptake increased by 1.0 mL/kg/min, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved by 10.5 points, and NT-proBNP declined by 88%. At week 39 of the open-label extension, in which all 42 patients enrolled, the complete LVOT-G response rate was 88%. Adverse events were mild to moderate in severity, and none led to treatment interruption or discontinuation, the companies said. No new safety signals were identified during the 12-week study period. The trial randomized patients 1:1:1 to oral HRS-1893 at 20 mg twice daily (titrated up to 60 mg), 40 mg twice daily (up to 80 mg), or 40 mg once daily (up to 120 mg), with individual dose adjustments permitted based on LVEF and Valsalva LVOT-G assessments. The primary endpoint was change in Valsalva LVOT-G from baseline to week 12. The companies reported that 89% of patients were managed at 40 mg or 60 mg twice daily with minimal or no titration. The study was open-label, and no placebo arm was included, which limits interpretation of the magnitude of observed changes. Efficacy data from the once-daily group and full between-group comparative analyses were not disclosed in detail. The data are based on 42 patients, and the open-label extension findings remain preliminary. HRS-1893 is described by the companies as a selective cardiac myosin inhibitor intended to reduce hypercontractility in hypertrophic cardiomyopathy. The oHCM field already includes Bristol Myers Squibb’s mavacamten, approved by the US FDA in 2022, and aficamten. While cross-trial comparisons should be interpreted cautiously because endpoint definitions and trial designs differ, mavacamten was associated with a 48.1% rate of Valsalva LVOT gradient <30 mmHg at week 30 in EXPLORER-CN, while aficamten achieved a 49.3% rate of Valsalva LVOT gradient <30 mmHg at week 24 in SEQUOIA-HCM. Despite numerically higher response rates, the open-label design and small sample size mean HRS-1893’s apparent efficacy advantage over mavacamten and aficamten remains unproven. HRS-1893 was developed by Hengrui, with rights licensed outside of Greater China licensed to Braveheart in a September 2025 deal. Hengrui is leading a strong clinical development program, with a dose finding Phase II in symptomatic oHCM already completed, an ongoing Phase II in nHCM, and an ongoing Phase III study in oHCM in China (NCT07021976). Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 2Drug ApprovalPhase 3

30 Mar 2026

·endpoints.news

Braveheart Bio posts promising China data in heart disease where Bristol Myers, Cytokinetics have drugs

The heart drug that Braveheart Bio licensed from China’s Jiangsu Hengrui Pharmaceuticals has shown promise in a mid-stage trial, according to data released Monday. The pill is intended to treat obstructive hypertrophic cardiomyopathy (oHCM), a disease in which the heart muscle thickens and creates a blockage that impairs the organ’s ability to pump blood. The drug, called BHB-1893 or HRS-1893, is a cardiac myosin inhibitor (CMI), like Bristol Myers Squibb’s Camzyos and Cytokinetics’ newly approved Myqorzo. In an open-label study run by Hengrui in China, 42 patients given Braveheart’s drug were found to have less difficulty pumping blood out of the heart’s left ventricle, as shown by reductions in a measure known as left ventricular outflow tract gradient (LVOT-G). Between 50% and 86% of the patients got to normal LVOT-G levels after three months’ treatment with the drug. The 86% response was seen with the middle dose tested in the trial. “We are seeing very rapid and deep normalization of the gradient that forms in this disease [which] is one of the key things that drives symptoms, and ultimately heart failure, in these patients,” Braveheart CEO Travis Murdoch told Endpoints News . The data were released at the American College of Cardiology’s annual meeting. All the patients then entered an extension period, and after roughly nine months, 88% of the patients had a normal LVOT-G level. “That, to us, is an impressive result, one that speaks to potential differentiation,” Murdoch said. Braveheart bought its rights to the drug last September , in a deal worth $65 million in upfront cash and stock, plus a large set of incentives worth as much as $1.01 billion. Hengrui will keep the rights in Greater China, while Braveheart has the rest of the world. BHB/HRS-1893 is already in a Hengrui-run China-based Phase 3 trial, using a dose of up to 80 mg. Murdoch said that historically there has been a high degree of consistency in terms of how patients respond to CMI therapy. This could suggest that the data could be relevant globally. But the FDA has been reluctant to accept China-only trial data. Braveheart is aiming to kick off its own Phase 3 in the US this year. The coming late-stage data might have implications for Braveheart as a company. Murdoch has already sold the immunology-focused company HI-Bio to Biogen for $1.15 billion in 2024. “HI-Bio was a great, great partnership we ultimately had with Biogen,” Murdoch said. But no deal is imminent for Braveheart, it seems, with Murdoch pointing out how well-funded the company is. Since HCM is an orphan indication, the company believes it can market the drug alone. “We believe we can take [it] all the way. Certainly we’re planning for that, and we’ll see what the future holds,” Murdoch said. That will mean taking on Bristol Myers and Cytokinetics, so any advantage will count. Murdoch said he doesn’t think BHB/HRS-1893 will have worries about drug-drug interactions, a concern with Camzyos, though not with Myqorzo. Braveheart’s chief scientific officer Marc Evanchik points to the drug’s swift action as another differentiating factor, with the effect on outflow tract gradient manifesting within a few days. “That is game-changing in this industry, because the current agents are taking weeks to months to titrate to an effective dose,” he said, crediting the drug’s pharmacokinetic profile. “We don’t believe all CMIs are built the same. We think this one’s got deeper effects on efficacy and enhanced safety.” None of the patients in the trial paused or quit treatment because of side effects. And importantly, none of the patients saw their left ventricular ejection fraction — another marker of the heart’s pumping ability — fall below 55%. This is a limiting factor in the use of Camzyos and Myqorzo; dosing with these drugs must be reduced or stopped if a patient’s ejection fraction drops below 50%. BHB/HRS-1893 should also have data coming in a different form of the disease — non-obstructive HCM, in which there is no blockage in the heart, but pumping ability is still diminished. About a third of patients with HCM have the non-obstructive form. A China-based Phase 2 study of BHB/HRS-1893 in non-obstructive HCM should read out by midyear. Notably, Camzyos’ pivotal trial in this condition failed . A pivotal trial of Myqorzo in nHCM is due to yield data in the coming months.

Phase 3Phase 2Clinical ResultDrug Approval

18 Mar 2026

·www.biospace.com

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - March 18, 2026

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of common stock and 5,719 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in February and March 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $60.06 per share, which is equal to the closing price of the Company’s common stock on March 13, 2026 and will vest over 4 years, with 1/4 th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48 th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted. The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ ( aficamten ) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten , an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology. For additional information about Cytokinetics, visit and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757

Drug Approval

100 Deals associated with Aficamten

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertrophic obstructive cardiomyopathy	China	Cytokinetics, Inc.	16 Dec 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	United States	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	China	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Japan	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Argentina	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Australia	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Brazil	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Canada	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Denmark	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	France	Cytokinetics, Inc.	30 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Germany	Cytokinetics, Inc.	30 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05186818 (SEQUOIA-HCM, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	282	Aficamten (Aficamten up to 20 mg)	zqweuuucvb(pvegkuqyqp) = jjsyeskcuy jkfgwfunov (tjwpnivwhw, 0.25) View more	-	03 Mar 2026
				Placebo to match aficamten (Placebo to Match Aficamten)	zqweuuucvb(pvegkuqyqp) = onhofrqaqp jkfgwfunov (tjwpnivwhw, 0.25) View more
NCT04219826 (REDWOOD-HCM Cohort 4 \| REDWOOD-HCM, CTgov)	Phase 2	Cardiomyopathy, Hypertrophic	96	CK-3773274 (Cohort 1 (oHCM) - Aficamten)	ovkqlmfwtb = zdeaczuzam dvosmrkplk (xrlitvnlim, iwcxufqhpi - tygcqbhlvp) View more	-	24 Feb 2026
				CK-3773274 (Cohort 2 (oHCM) - Aficamten)	ovkqlmfwtb = vlwphqyuuv dvosmrkplk (xrlitvnlim, uwxpcopssq - moyzxzmqcw) View more
NCT06412666 \| NCT05186818 (CEDAR-HCM, Pubmed \| Circ Heart Fail)	Phase 3	Hypertrophic obstructive cardiomyopathy	65	Aficamten	pypwpzeccn(cmojatfjmv) = tobuumugao urdpykbufo (vumfwvpwsb )	Positive	05 Dec 2025
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten 5 to 20 mg	kopxtvvxcm(wjhskayogk) = fqbsydojgz xzrephpksu (xgmlfviezm ) View more	Positive	01 Dec 2025
				Metoprolol 50 to 200 mg	-
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	ethqoqdcep(ngdqiiodcm) = utebvcxgnq sngnahqfbh (cphuqysulw ) View more	Positive	01 Nov 2025
				Metoprolol	ethqoqdcep(ngdqiiodcm) = bvgbelpbry sngnahqfbh (cphuqysulw ) View more
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	rprkxfvhrp(fntbyzwrpp): Difference = 7.8 (95.0% CI, 3.3 - 12.3), P-Value = < 0.001 View more	Positive	01 Nov 2025
				Metoprolol
NCT05767346 (MAPLE-HCM, Company_Website) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	-	Aficamten	isemmonxix(eddjpodgew) = oxeewcoiwk zzfndeyrba (qaxghclcji ) View more	Superior	29 Sep 2025
				Metoprolol	-
NCT04848506 (FOREST-HCM, Company_Website) Manual	Phase 2/3	Hypertrophic Cardiomyopathy without Obstruction	34	Aficamten (post-REDWOOD-HCM Cohort 4)	dggyodajvj(fyuwkxixaj) = qhidadcaqc sssexmdszh (bogttwhmwp ) View more	Positive	29 Sep 2025
NCT05767346 (MAPLE-HCM, Pubmed \| N Engl J Med) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	fudpmmyzwd(ecwgrgudnz) = ytqasoorpj eqkozhotmt (gnbqmtanbc, 0.5 - 1.7)	Superior	11 Sep 2025
				Metoprolol	fudpmmyzwd(ecwgrgudnz) = zzxnocptww eqkozhotmt (gnbqmtanbc, -1.7 to -0.8)
NCT04848506 (FOREST-HCM, Pubmed \| JACC Heart Fail)	Phase 2/3	Hypertrophic obstructive cardiomyopathy	213	Aficamten 5 mg	cfmslmiaqd(kldltbkfrx) = 2 (4.3%) asymptomatic and transient instances of left ventricular ejection fraction <50% (range: 47%-49%), neither resulting in drug discontinuation eqclwtzkua (fdnkvmqwux ) View more	Positive	01 Aug 2025
				Aficamten ≤20 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Aficamten

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation